Aligos Therapeutics IncNASDAQ:ALGS
- LAST PRICE9.8300
- TODAY'S CHANGE (%)0.3500 (3.6920%)
- Bid / Lots9.5500/ 1
- Ask / Lots10.0000/ 1
- Open / Previous Close9.5100 / 9.4800
- Day Range
- 52 Week Range
- Volume78,807
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALGS |
|---|---|---|
| 09:32 ET | 671 | 9.51 |
| 09:35 ET | 100 | 9.49 |
| 09:37 ET | 200 | 9.44 |
| 09:42 ET | 500 | 9.44 |
| 09:48 ET | 800 | 9.42 |
| 09:51 ET | 1585 | 9.4 |
| 10:00 ET | 145 | 9.318 |
| 10:02 ET | 100 | 9.62 |
| 10:04 ET | 100 | 9.5623 |
| 10:06 ET | 950 | 9.63 |
| 10:11 ET | 3460 | 9.7799 |
| 10:13 ET | 1950 | 9.575 |
| 10:18 ET | 1960 | 9.4631 |
| 10:24 ET | 750 | 9.4639 |
| 10:33 ET | 2150 | 9.6 |
| 10:47 ET | 200 | 9.5333 |
| 11:12 ET | 100 | 9.5 |
| 11:23 ET | 100 | 9.4 |
| 11:32 ET | 200 | 9.42 |
| 11:36 ET | 142 | 9.44 |
| 11:43 ET | 6932 | 9.7 |
| 11:45 ET | 400 | 9.6335 |
| 11:54 ET | 1000 | 9.5001 |
| 11:56 ET | 200 | 9.74 |
| 11:57 ET | 400 | 9.5 |
| 11:59 ET | 700 | 9.7604 |
| 12:08 ET | 200 | 9.655 |
| 12:15 ET | 1970 | 9.55 |
| 12:32 ET | 100 | 9.75 |
| 12:48 ET | 200 | 9.72 |
| 12:51 ET | 1500 | 9.56 |
| 01:33 ET | 700 | 9.65 |
| 01:38 ET | 600 | 9.7 |
| 01:40 ET | 995 | 9.75 |
| 01:49 ET | 200 | 9.73 |
| 02:23 ET | 100 | 9.6447 |
| 02:39 ET | 1500 | 9.77 |
| 02:56 ET | 300 | 9.7 |
| 03:03 ET | 100 | 9.7 |
| 03:08 ET | 13867 | 9.642 |
| 03:15 ET | 100 | 9.5022 |
| 03:17 ET | 1912 | 9.7199 |
| 03:21 ET | 4408 | 9.7199 |
| 03:28 ET | 1500 | 9.72 |
| 03:30 ET | 200 | 9.72 |
| 03:32 ET | 1646 | 9.8 |
| 03:33 ET | 100 | 9.88 |
| 03:35 ET | 500 | 9.7286 |
| 03:37 ET | 1000 | 9.7335 |
| 03:42 ET | 600 | 9.75 |
| 03:44 ET | 1500 | 9.8488 |
| 03:46 ET | 700 | 9.84 |
| 03:48 ET | 500 | 9.78 |
| 03:51 ET | 10559 | 9.59 |
| 04:00 ET | 1227 | 9.83 |
Oct 30, 2024
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
Oct 23, 2024
DJ Aligos Therapeutics Price Target Maintained With a $75.00/Share by HC Wainwright & Co., from 7:35AM ET on Wednesday Oct 23, 2024 by Dow Jones
7:35AM ET on Wednesday Oct 23, 2024 by Dow Jones
Oct 22, 2024
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184, from 8:00AM ET on Tuesday Oct 22, 2024 by Dow Jones
8:00AM ET on Tuesday Oct 22, 2024 by Dow Jones
Oct 15, 2024
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024, from 9:00AM ET on Tuesday Oct 15, 2024 by Dow Jones
9:00AM ET on Tuesday Oct 15, 2024 by Dow Jones
Oct 11, 2024
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 8:00AM ET on Friday Oct 11, 2024 by Dow Jones
8:00AM ET on Friday Oct 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aligos Therapeutics Inc | 30.3M | -0.4x | --- |
ImmuCell Corp | 28.1M | -7.0x | --- |
Carisma Therapeutics Inc | 43.6M | -0.6x | --- |
Gritstone bio Inc | 3.2M | 0.0x | --- |
Response Genetics Inc | 40.0 | 0.0x | --- |
Immunoprecise Antibodies Ltd | 12.4M | -0.6x | --- |
Company Information
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.
Contact Information
- Headquarters
- One Corporate Dr., 2nd Floor, 2nd FloorSOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 302-658-7581
- Fax
- 302-655-5049
Executives
- Chairman of the Board, President, Chief Executive Officer
- Lawrence Blatt
- Chief Financial Officer, Executive Vice President
- Lesley Calhoun
- Executive Vice President, Chief Scientific Officer
- Julian Symons
- Executive Vice President
- Matthew Mcclure
- Chief Medical Officer
- Hardean Achneck
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.3M |
|---|---|
Revenue (TTM) | $8.0M |
Shares Outstanding | 3.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.11 |
EPS | $-25.99 |
Book Value | $15.36 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 3.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,173.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
